Cjc+Dac

CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analog distinguished by a long half-life of roughly 8 days. The DAC modification binds the peptide so that it persists in the body far longer than standard CJC-1295, allowing users to inject only once or twice a week while keeping growth hormone levels elevated. As with most peptides, it is sold as a research chemical requiring reconstitution and subcutaneous injection, so purity and storage matter.

A note of caution on evidence: this compound carries only a C grade, and that grade is based on just the 2 studies cited here, because the full research corpus is not yet available. That is a thin foundation, and readers should treat broader efficacy claims with corresponding skepticism. The two citations are limited: one in vitro study confirms that the DAC modification extends the half-life to about 8 days and enables weekly dosing, and one observational study reports sustained IGF-1 elevation with good tolerability in healthy subjects. That's the extent of the directly cited human and lab support, so much of what's said about real-world body-composition results rests on extrapolation from CJC-1295 generally rather than robust trial data on the DAC version.

What the research shows, then, is narrow but consistent: the DAC version does what it claims mechanically, namely prolonging action and raising IGF-1, while appearing reasonably well tolerated in the limited data available.

Who should be cautious: anyone who values a natural GH rhythm. The main trade-off is convenience versus physiology, because constant elevation departs from the body's normal pulsatile GH pattern, and some users deliberately prefer the non-DAC form for a more natural release. Because the peptide acts for days, any side effects, such as water retention, numbness, or joint pain, may also persist longer than with shorter-acting options.

Community sentiment is essentially neutral and very sparse. Across just 3 community reports, 100% were neutral, with discussion centered on how to reconstitute CJC with DAC. That sample is far too small to read much into.

On dosing, the standard is 1-2 mg once or twice weekly via subcutaneous injection, with a consistent weekly schedule keeping levels steady. In terms of effectiveness, the DAC form is generally well tolerated and convenient, though some prefer non-DAC for the more natural pulsatile pattern; it tends to suit people who dislike frequent injections and want better adherence.

Availability is through peptide suppliers as a research chemical, where verifying purity and sourcing from reputable vendors is important. It is frequently compared directly with non-DAC CJC-1295, and the choice usually comes down to whether you prioritize dosing convenience or a more natural GH release pattern. Overall, the convenience is real, but the evidence here is genuinely limited, and the C grade should keep expectations grounded.